Myoglobins and creatine kinase are also elevated in the blood in embolisation in other locations. Blood cultures may be done to identify the organism responsible for any causative infection
Electrocardiography (ECG) for detecting myocardial infarction
Angioscopy using a flexible fiberoptic catheter inserted directly into an artery. Prevention
Prevention of atherosclerosis, which is a major risk factor of arterial embolism, can be performed e.g. by dieting, physical exercise and smoking cessation.In case of high risk for developing thromboembolism, antithrombotic medication such as warfarin or coumadin may be taken prophylactically. Antiplatelet drugs may also be needed. Treatment
Treatment is aimed at controlling symptoms and improving the interrupted blood flow to the affected area of the body.Medications include:

Antithrombotic medication. These are commonly given because thromboembolism is the major cause of arterial embolism. Examples are:
Anticoagulants (such as warfarin or heparin) and antiplatelet medication (such as aspirin, ticlopidine, and clopidogrel) can prevent new clots from forming
Thrombolytics (such as streptokinase) can dissolve clots
Painkillers given intravenously
Vasodilators to relax and dilate blood vessels.Appropriate drug treatments successfully produce thrombolysis and removal of the clot in 50% to 80% of all cases.Antithrombotic agents may be administered directly onto the clot in the vessel using a flexible catheter (intra-arterial thrombolysis).
Pure enclomifene isomer is likely to be more effective than clomifene at treating gynecomastia, because of the lack of the zuclomifene isomer (as noted above). Due to its long half-life, zuclomifene can be detected in urine for at least 261 days after discontinuation (261 days after discontinuation with a half-life of 30 days, there is still 0.24% of the peak level of zuclomifene being excreted, whereas with a half-life of 10 hours, enclomifene reaches the same 0.24% level in less than 4 days). Because of its potential for boosting testosterone, clomifene is listed as banned for use by competitive sportsmen, both in and out of competition, by the World Anti-Doping Agency, absent an organic etiology of primary hypogonadism. Contraindications
Contraindications include an allergy to the medication, pregnancy, prior liver problems, abnormal vaginal bleeding of unclear cause, ovarian cysts other than those due to polycystic ovarian syndrome, unmanaged adrenal or thyroid problems, and pituitary tumors. Side effects
The most common adverse drug reaction associated with the use of clomifene (>10% of people) is reversible ovarian enlargement.Less common effects (1–10% of people) include visual symptoms (blurred vision, double vision, floaters, eye sensitivity to light, scotomata), headaches, vasomotor flushes (or hot flashes), light sensitivity and pupil constriction, abnormal uterine bleeding and/or abdominal discomfort.Rare adverse events (<1% of people) include: high blood level of triglycerides, liver inflammation, reversible baldness and/or ovarian hyperstimulation syndrome.Clomifene can lead to multiple ovulation, hence increasing the chance of twins (10% of births instead of ~1% in the general population) and triplets.